<DOC>
	<DOCNO>NCT01187446</DOCNO>
	<brief_summary>The purpose study determine vorinostat combine low-dose total skin electron beam therapy ( TSEBT ) offer superior clinical benefit ( efficacy &amp; safety ) low-dose TSEBT alone .</brief_summary>
	<brief_title>Low-dose ( 12 Gy ) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy Mycosis Fungoides</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>A patient eligible inclusion follow criterion apply : 1 . Biopsyconfirmed mycosis fungoides , clinical stage IBIIIB . 2 . Patients must fail intolerant least one prior systemic skindirected therapy . This may include topical steroid use primary therapy MF . 3.18 year age old . 4.Eastern Cooperative Oncology Group ( ECOG ) &lt; = 2 . 5.Adequate bone marrow function : WBC &gt; 2000/uL ; platelet count &gt; 75,000/mm3 ; ANC &gt; 1000 . Patients use colony stimulating factor . 6.Required wash period prior therapy Topical therapy : 2 week Systemic biologic , monoclonal antibody , chemotherapy : 4 week Phototherapy radiotherapy ( exclude TSEBT ) : 4 week Other investigational therapy : 4 week Note : patient rapidly progressive disease may treat early require washout period ; however , circumstance must discuss approve protocol director primary site ( Stanford ) . 7.Women childbearing potential ( WOCBP ) must negative serum pregnancy test . 8.WOCBP must agree use effective contraception , define oral contraceptive , intrauterine device , double barrier method ( condom plus spermicide diaphragm ) abstain sexual intercourse . WOCBP include female experience menarche undergone successful surgical sterilization postmenopausal ( define amenorrhea 12 consecutive month ) . 9.Male subject must willing use appropriate method contraception ( e.g. , condom ) abstain sexual intercourse inform sexual partner must also use reliable method contraception ( e.g. , birth control pill ) study . 10.Adequate hepatic function : bilirubin &lt; = 1.5 x upper limit normal ( ULN ) , AST &lt; = 2.5 x UNL , ALT &lt; = 2.5 x UNL , alkaline phosphatase ( liver fraction ) &lt; = 2.5 x ULN 11.Adequate renal function : creatinine &lt; =1.5 x UNL OR creatinine clearance &lt; =60 mL/min patient creatinine level &gt; 1.5 X institutional ULN 12.Metabolic parameter : potassium level 3.5 4.5 , magnesium level 1.5 2.5 13.Ability understand sign write informed consent document . 14.Ability comply treatment schedule A patient eligible inclusion follow criterion apply : 1 . Prior course TSEBT ( Note : localize skindirected radiotherapy allow administer least 4 week prior initiation study ) . 2 . Concomitant use anticancer therapy immune modifier . 3 . Prior allogeneic autologous transplant . 4 . Active infection receive intravenous antibiotic , antiviral , antifungal agent within 2 week prior start study drug . 5 . Known history human immunodeficiency virus ( HIV ) , hepatitis B C. 6 . History prior malignancy exception cervical intraepithelial neoplasia , nonmelanoma skin cancer , adequately treat localized prostate carcinoma ( PSA &lt; 1.0 ) . Patients history malignancy must undergo potentially curative therapy evidence disease five year . 7 . Patient uncontrolled intercurrent illness , condition , circumstance could limit compliance study , include , limited following : active infection , acute chronic graft versus host disease , symptomatic congestive heart failure , unstable angina pectoris , medically significant cardiac arrhythmia , uncontrolled diabetes mellitus hypertension , psychiatric condition . 8 . Recent ( past 6 month ) medically significant cardiac event ( i.e . myocardial infarction , cardiac surgery . 9 . Congenital long QT syndrome . 10 . QTc interval &gt; 480 msec screen ECG . 11 . Proven suspect stage IV disease include patient B2 ( Sezary syndrome ) , N3 ( frank LN disease ) , M1 ( visceral disease ) categories ; presence reactive dermatopathic lymphadenopathy ( N12 ) limit blood involvement ( B1 ) permit . 12 . ECOG performance status &gt; 2 . 13 . Pregnant lactating . 14 . Unwilling use reliable birth control method . 15 . Any medical issue , include laboratory abnormality , deem Investigator likely interfere patient participation . 16 . Unwilling unable provide inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Cutaneous T-cell Lymphoma</keyword>
</DOC>